» Articles » PMID: 29985410

Optimization of a MT1-MMP-targeting Peptide and Its Application in Near-infrared Fluorescence Tumor Imaging

Overview
Journal Sci Rep
Specialty Science
Date 2018 Jul 10
PMID 29985410
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Membrane type 1 metalloproteinase (MT1-MMP) is an important regulator of cancer invasion, growth and angiogenesis, thus making it an attractive target for cancer imaging and therapy. A non-substrate peptide (MT1-AF7p) that bonded to the "MT-Loop" region of MT1-MMP was identified by using a phage-displayed peptide library and was used to image the MT1-MMP expression in vivo through optical imaging. However, the substrate in the screening did not have a 3D structure, thus resulting in a loose bonding of MT1-AF7p. To simulate the real conformation of the "MT-Loop" and improve the performance of MT1-AF7p, molecular simulations were performed, because this strategy provides multiple methods for predicting the conformation and interaction of proteinase in 3D. In view of the binding site of the receptor-ligand interactions, histidine 4 was selected for mutation to achieve an increased affinity effect. The optimized peptides were further identified and conformed by atomic force microscopy, isothermal titration calorimetry, cell fluorescence imaging in vitro, and near-infrared fluorescence tumor optical imaging in vivo. The results revealed that the optimized peptide with a mutation of histidine 4 to arginine has the highest affinity and specificity, and exhibited an increased fluorescence intensity in the tumor site in optical imaging.

Citing Articles

Exploring the Integrated Role of AKT2, CD44v6, And MT1-MMP as Predictors of Axillary Lymph Node Metastasis in Invasive Breast Carcinoma of No Special Type.

Rustamadji P, Wiyarta E, Bethania K Iran J Pathol. 2022; 17(4):480-490.

PMID: 36532641 PMC: 9745758. DOI: 10.30699/IJP.2022.551244.2866.


Progresses in Fluorescence Imaging Guidance for Bone and Soft Tissue Sarcoma Surgery.

Chen Z, Huang H, He S, Wang Y, Cai L, Xie Y Front Oncol. 2022; 12:879697.

PMID: 35860548 PMC: 9289289. DOI: 10.3389/fonc.2022.879697.


Current status of targeted microbubbles in diagnostic molecular imaging of pancreatic cancer.

Jugniot N, Bam R, Meuillet E, Unger E, Paulmurugan R Bioeng Transl Med. 2021; 6(1):e10183.

PMID: 33532585 PMC: 7823123. DOI: 10.1002/btm2.10183.


Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib.

Yin N, Yu H, Zhang X, Lv X Drug Des Devel Ther. 2020; 14:4465-4475.

PMID: 33122890 PMC: 7591159. DOI: 10.2147/DDDT.S270303.

References
1.
English W, Holtz B, Vogt G, Knauper V, Murphy G . Characterization of the role of the "MT-loop": an eight-amino acid insertion specific to progelatinase A (MMP2) activating membrane-type matrix metalloproteinases. J Biol Chem. 2001; 276(45):42018-26. DOI: 10.1074/jbc.M107783200. View

2.
Sritharan K, Quinn A, Taatjes D, Jena B . Binding contribution between synaptic vesicle membrane and plasma membrane proteins in neurons: an AFM study. Cell Biol Int. 1999; 22(9-10):649-55. DOI: 10.1006/cbir.1998.0319. View

3.
Stamenkovic I . Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol. 2003; 200(4):448-64. DOI: 10.1002/path.1400. View

4.
Atkinson J, Falconer R, Edwards D, Pennington C, Siller C, Shnyder S . Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases. Cancer Res. 2010; 70(17):6902-12. PMC: 2933508. DOI: 10.1158/0008-5472.CAN-10-1440. View

5.
Cheng J, Liu H, Lee C, Chen M, Lin W, Tsai F . Matrix metalloproteinase 14 modulates diabetes and Alzheimer's disease cross-talk: a meta-analysis. Neurol Sci. 2017; 39(2):267-274. DOI: 10.1007/s10072-017-3166-4. View